Cancer
Malignant Ovarian Neoplasm
CI-CAN-00003205Explore in graph →
Top-level685 active trials5 approved drugs83 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00003205Explore in graph →
Clinical trials
3,087 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (437)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01104675 | Study of Oral ENMD-2076 Administered to Patients With Ovarian Cancer | completed | Phase 2 | 64 | CASI pharmaceuticals, Inc.INDUSTRY | 2 | Aug 6, 2014 | clinicaltrials |
| NCT00004206 | Oxaliplatin and Fluorouracil in Treating Patients With Recurrent Ovarian Cancer | unknown | Phase 2 | — | University of LeicesterOTHER | 1 | Jun 24, 2014 | clinicaltrials |
| Oxaliplatin, Gemcitabine and Bevacizumab in Women With Recurrent Mullerian Carcinoma |
| terminated |
| Phase 2 |
| 19 |
| Dana-Farber Cancer InstituteOTHER |
| 1 |
| Jun 19, 2014 |
| clinicaltrials |
| NCT01163552 | Heated Chemotherapy for Cancers That Have Spread to the Chest Cavity | completed | Phase 2 | 5 | St. Luke's-Roosevelt Hospital CenterOTHER | 1 | Jun 13, 2014 | clinicaltrials |
| NCT00245102 | Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma | completed | Phase 2 | 147 | National Cancer Institute (NCI)NIH | 1 | May 23, 2014 | clinicaltrials |
| NCT00003449 | Combination Chemotherapy in Treating Patients With Platinum-Resistant Recurrent Ovarian Cancer | completed | Phase 2 | 35 | University of Southern CaliforniaOTHER | 1 | May 22, 2014 | clinicaltrials |
| NCT00183794 | Clinical Trial of Docetaxel in Combination With Gemcitabine in Platinum-Resistant Ovarian Cancer and Primary Peritoneal Carcinoma | completed | Phase 2 | 20 | University of Southern CaliforniaOTHER | 1 | May 22, 2014 | clinicaltrials |
| NCT00083122 | Cisplatin and Flavopiridol in Treating Patients With Advanced Ovarian Epithelial Cancer or Primary Peritoneal Cancer | completed | Phase 2 | 45 | National Cancer Institute (NCI)NIH | 1 | May 21, 2014 | clinicaltrials |
| NCT00093496 | Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Recurrent Advanced Ovarian Epithelial or Peritoneal Cavity Cancer | completed | Phase 2 | 29 | National Cancer Institute (NCI)NIH | 1 | May 20, 2014 | clinicaltrials |
| NCT00126542 | Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer | completed | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | May 14, 2014 | clinicaltrials |
| NCT00170677 | Topotecan Weekly Versus Topotecan Day 1-5 in Patient With Platin-resistant Ovarian Cancer | completed | Phase 2 | 194 | North Eastern German Society of Gynaecological OncologyOTHER | 1 | May 14, 2014 | clinicaltrials |
| NCT02132988 | Trial of Active Immunotherapy With Globo H-KLH (OPT-822/821) in Women Who Have Non-Progressive Ovarian Cancer | unknown | Phase 2 | 110 | Mackay Memorial HospitalOTHER | 1 | May 7, 2014 | clinicaltrials |
| NCT00436644 | Lapatinib and Topotecan in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Did Not Respond to Cisplatin or Carboplatin | completed | Phase 2 | 18 | Mayo ClinicOTHER | 1 | Apr 16, 2014 | clinicaltrials |
| NCT00086892 | Cetuximab and Carboplatin in Treating Patients With Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer | completed | Phase 2 | — | Gynecologic Oncology GroupNETWORK | 5 | Feb 14, 2014 | clinicaltrials |
| NCT00087087 | Pemetrexed Disodium in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer | completed | Phase 2 | 51 | Gynecologic Oncology GroupNETWORK | 1 | Feb 14, 2014 | clinicaltrials |
| NCT00504257 | Avastin in Combination With Docetaxel in Ovarian/Fallopian Tube/Peritoneum Carcinoma | completed | Phase 2 | 45 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Feb 6, 2014 | clinicaltrials |
| NCT00553683 | Cyclophosphamide, Radiation Therapy, and Poly ICLC in Treating Patients With Unresectable, Recurrent, Primary, or Metastatic Liver Cancer | unknown | Phase 1 / Phase 2 | 50 | Rutgers, The State University of New JerseyOTHER | 1 | Jan 14, 2014 | clinicaltrials |
| NCT01639885 | Chemo-immunotherapy (Gemcitabine, Interferon-alpha 2b and p53 SLP) in Patients With Platinum-resistant Ovarian Cancer(CHIP) | completed | Phase 1 / Phase 2 | 15 | Leiden University Medical CenterOTHER | 1 | Jan 7, 2014 | clinicaltrials |
| NCT00003064 | Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Persistent Epithelial Ovarian Cancer, Fallopian Tube, or Primary Peritoneal Cancer | unknown | Phase 1 / Phase 2 | 30 | Herbert Irving Comprehensive Cancer CenterOTHER | 1 | Jan 6, 2014 | clinicaltrials |
| NCT00003560 | Docetaxel Plus Carboplatin in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | unknown | Phase 2 | 40 | Herbert Irving Comprehensive Cancer CenterOTHER | 1 | Jan 6, 2014 | clinicaltrials |
| NCT00003718 | Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma | unknown | Phase 2 | 25 | Herbert Irving Comprehensive Cancer CenterOTHER | 1 | Jan 6, 2014 | clinicaltrials |
| NCT01131039 | Safety and Efficacy Study of Gemcitabine Plus Bevacizumab in Patients With Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer | withdrawn | Phase 2 | 0 | Emory UniversityOTHER | 0 | Dec 20, 2013 | clinicaltrials |
| NCT00096239 | CP-547,632 in Treating Patients With Recurrent or Persistent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | completed | Phase 2 | — | Jonsson Comprehensive Cancer CenterOTHER | 1 | Dec 19, 2013 | clinicaltrials |
| NCT00021385 | Squalamine Lactate Plus Carboplatin in Treating Patients With Recurrent or Refractory Stage III or Stage IV Ovarian Cancer | unknown | Phase 2 | — | Jonsson Comprehensive Cancer CenterOTHER | 1 | Dec 18, 2013 | clinicaltrials |
| NCT01982487 | Vaccine Therapy and IDO1 Inhibitor INCB024360 in Treating Patients With Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Are in Remission | withdrawn | Phase 1 / Phase 2 | 0 | Roswell Park Cancer InstituteOTHER | 0 | Dec 18, 2013 | clinicaltrials |
| NCT00025441 | Combination Chemotherapy in Treating Children With Metastatic Rhabdomyosarcoma or Other Malignant Mesenchymal Tumors | completed | Phase 2 | — | Societe Internationale d'Oncologie PediatriqueOTHER | 3 | Dec 4, 2013 | clinicaltrials |
| NCT01079832 | Stereotactic Radiosurgery Using CyberKnife in Treating Women With Advanced or Recurrent Gynecological Malignancies | completed | Phase 2 | 50 | Case Comprehensive Cancer CenterOTHER | 1 | Nov 28, 2013 | clinicaltrials |
| NCT00617773 | Hu3S193 in Treating Women With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | completed | Phase 2 | 31 | Recepta BiopharmaINDUSTRY | 1 | Nov 26, 2013 | clinicaltrials |
| NCT00053833 | S0025 Irinotecan in Treating Patients With Refractory Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | terminated | Phase 2 | 2 | SWOG Cancer Research NetworkNETWORK | 2 | Nov 8, 2013 | clinicaltrials |
| NCT00004064 | Monoclonal Antibody Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer | unknown | Phase 2 | 102 | AltaRexINDUSTRY | 2 | Nov 6, 2013 | clinicaltrials |
| NCT00005025 | Gene Therapy in Treating Women With Refractory or Relapsed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer | unknown | Phase 2 | — | John Stoddard Cancer Center at Iowa Methodist Medical CenterOTHER | 1 | Nov 6, 2013 | clinicaltrials |
| NCT00017303 | Combination Chemotherapy Plus IM-862 in Treating Patients With Resected Stage III Ovarian Cancer or Primary Peritoneal Cancer | unknown | Phase 2 | — | CytranINDUSTRY | 1 | Nov 6, 2013 | clinicaltrials |
| NCT00721890 | Green Tea Intake for the Maintenance of Complete Remission in Women With Advanced Ovarian Carcinoma(DBGT-OC-CR) | completed | Phase 2 | 16 | CHU de Quebec-Universite LavalOTHER | 1 | Oct 24, 2013 | clinicaltrials |
| NCT00526149 | BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors | completed | Phase 2 | 76 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 1 | Oct 7, 2013 | clinicaltrials |
| NCT00677079 | Single Arm Study of BSI-201 in Patients With BRCA-1 or BRCA-2 Associated Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 2 | 12 | SanofiINDUSTRY | 1 | Oct 1, 2013 | clinicaltrials |
| NCT00003733 | Sequential Chemotherapy in Treating Patients With Residual Disease Following Surgery for Stage IIB, Stage III, or Stage IV Ovarian Cancer | unknown | Phase 2 | 40 | SmithKline BeechamINDUSTRY | 1 | Sep 20, 2013 | clinicaltrials |
| NCT00036712 | Light-Emitting Diode Therapy in Preventing Mucositis in Children Receiving Chemotherapy With or Without Radiation Therapy Before Bone Marrow Transplantation | unknown | Phase 2 | 80 | Medical College of WisconsinOTHER | 1 | Sep 20, 2013 | clinicaltrials |
| NCT00002487 | Methotrexate Plus Dipyridamole in Treating Patients With Advanced Ovarian Cancer | unknown | Phase 2 | — | Ottawa Regional Cancer CentreOTHER | 1 | Sep 17, 2013 | clinicaltrials |
| NCT00831636 | A Phase I/II Study of CP-4055 in Patients With Platinum Resistant Ovarian Cancer | completed | Phase 1 / Phase 2 | 28 | Clavis PharmaINDUSTRY | 2 | Sep 13, 2013 | clinicaltrials |
| NCT00085527 | FR901228 in Treating Patients With Relapsed or Refractory Advanced Ovarian Epithelial Cancer | withdrawn | Phase 2 | 0 | University of ChicagoOTHER | 1 | Sep 5, 2013 | clinicaltrials |
| NCT00004876 | Carboplatin With or Without Thalidomide in Treating Patients With Ovarian Epithelial Cancer | completed | Phase 2 | 30 | Cancer Research UKOTHER | 1 | Aug 26, 2013 | clinicaltrials |
| NCT00006942 | Bryostatin 1 and Cisplatin in Treating Patients With Advanced Recurrent or Residual Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 2 | 32 | National Cancer Institute (NCI)NIH | 1 | Aug 26, 2013 | clinicaltrials |
| NCT00964626 | Paclitaxel and Cisplatin as First-Line Treatment for Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer | unknown | Phase 2 | 60 | Russian Academy of Medical SciencesOTHER | 1 | Aug 26, 2013 | clinicaltrials |
| NCT01100372 | Liposome-Encapsulated Doxorubicin Citrate With or Without Gemcitabine Hydrochloride in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer | unknown | Phase 2 | 154 | Medical University InnsbruckOTHER | 1 | Aug 26, 2013 | clinicaltrials |
| NCT00510653 | Gleevec Study for Patients With Ovarian Cancer | completed | Phase 2 | 73 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 23, 2013 | clinicaltrials |
| NCT00002538 | Laparoscopic Staging in Patients With Ovarian, Fallopian Tube, or Other Primary Abdominal Cancers | completed | Phase 2 | — | Gynecologic Oncology GroupNETWORK | 1 | Aug 20, 2013 | clinicaltrials |
| NCT01388621 | Carboplatin-based Chemotherapy With or Without Panitumumab in Platinum-sensitive Recurrent Ovarian Cancer(PROVE) | unknown | Phase 2 | 140 | WiSP Wissenschaftlicher Service Pharma GmbHOTHER | 1 | Aug 20, 2013 | clinicaltrials |
| NCT00003732 | Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Cancer | completed | Phase 2 | 80 | Rigshospitalet, DenmarkOTHER | 1 | Aug 12, 2013 | clinicaltrials |
Data updated 23 days agoSource updated Aug 6, 2014source: clinicaltrials